FDA Approves New Acute Lymphoblastic Leukemia Treatment

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Source: CancerNetwork - August 18, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news